1.Rosental B, Kowarsky M, Seita J, Corey DM, Ishizuka KJ, Palmeri KJ, Chen SY, Sinha R, Okamoto J, Mantalas G, Manni L, Raveh T, Clarke DN, Tsai JM, Newman AM, Neff NF, Nolan GP, Quake SR, Weissman IL, Voskoboynik A. Complex mammalian-like haematopoietic system found in a colonial chordate.Nature. 2018;564(7736):425-429
2.Messal HA, Alt S, Ferreira RMM, Gribben C, Wang VM, Cotoi CG, Salbreux G, Behrens A. Tissue curvature and apicobasal mechanical tension imbalance instruct cancer morphogenesis. Nature. 2019;566(7742):126-130.
3.Sánchez-Danés A, Larsimont JC, Liagre M, Muñoz-Couselo E, Lapouge G, Brisebarre A, Dubois C, Suppa M, Sukumaran V, Del Marmol V, Tabernero J, Blanpain C. A slow-cycling LGR5 tumour population mediates basal cell carcinoma relapse after therapy.Nature. 2018;562(7727):434-438
4.Mrna Choe J, Lin S, Zhang W, Liu Q, Wang L, Ramirez-Moya J, Du P, Kim W, Tang S, Sliz P, Santisteban P, George RE, Richards WG, Wong KK, Locker N, Slack FJ, Gregory RI. mRNA circularization by METTL3-eIF3h enhances translation and promotes oncogenesis. Nature. 2018;561(7724):556-560
5.Fu T, Coulter S, Yoshihara E, Oh TG, Fang S, Cayabyab F, Zhu Q, Zhang T, Leblanc M, Liu S, He M, Waizenegger W, Gasser E, Schnabl B, Atkins AR, Yu RT, Knight R, Liddle C, Downes M, Evans RM. FXR Regulates Intestinal Cancer Stem Cell Proliferation. Cell. 2019;176(5):1098-1112.
6.Gronke K, Hernández PP, Zimmermann J, Klose CSN, Kofoed-Branzk M, Guendel F, Witkowski M, Tizian C, Amann L, Schumacher F, Glatt H, Triantafyllopoulou A, Diefenbach A. Interleukin-22 protects intestinal stem cells against genotoxic stress. Nature. 2019;566(7743):249-253
7.Bahr C, von Paleske L, Uslu VV, Remeseiro S, Takayama N, Ng SW, Murison A, Langenfeld K, Petretich M, Scognamiglio R, Zeisberger P, Benk AS, Amit I, Zandstra PW, Lupien M, Dick JE, Trumpp A, Spitz F. A Myc enhancer cluster regulates normal and leukaemic haematopoietic stem cell hierarchies. Nature. 2018;553(7689):515-520.
8. Xu XL, Xing BC, Han HB, et al. The properties of tumor-initiating cells from a hepatocellular carcinoma patient's primary and recurrent tumor. Carcinogenesis, 2010, 31(2): 167-174.
9.Blackburn EH. Structure and function of telomeres. Nature, 1991, 350(6319): 569-573.
10.Palm W, de Lange T. How shelterin protects mammalian telomeres. Annual review of genetics, 2008, 42: 301-334.
11.Galati A, Micheli E, Alicata C, et al. TRF1 and TRF2 binding to telomeres is modulated by nucleosomal organization. Nucleic acids research, 2015, 43(12): 5824-5837.
12.Stone MD. Detailed view of human telomerase enzyme invites rethink of its structure. Nature. 2018;557(7704):174-175
13.Blackburn EH EE, Lin J. Human telomere biology: A contributory and interactive factor in aging, disease risks, and protection. Science, 2015, 350(6265): 1193-1198.
14.Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. European journal of cancer, 1997, 33(5): 787-791.
15.Zaret KS. The telomerase enzyme and liver renewal. Nature. 2018;556(7700):181-182
16.Wang S, Pike AM, Lee SS, et al. BRD4 inhibitors block telomere elongation. Nucleic acids research, 2017, 45(14): 8403-8410.
17.Benetti R, Garcia-Cao M, Blasco MA. Telomere length regulates the epigenetic status of mammalian telomeres and subtelomeres. Nature genetics, 2007, 39(2): 243-250.
18.Azzalin CM, Reichenbach P, Khoriauli L, et al. Telomeric repeat containing RNA and RNA surveillance factors at mammalian chromosome ends. Science, 2007, 318(5851): 798-801.
19.Cusanelli E, Chartrand P. Telomeric repeat-containing RNA TERRA: a noncoding RNA connecting telomere biology to genome integrity. Frontiers in genetics, 2015, 6: 143.
20.Deng Z, Norseen J, Wiedmer A, et al. TERRA RNA binding to TRF2 facilitates heterochromatin formation and ORC recruitment at telomeres. Molecular cell, 2009, 35(4): 403-413.
21.Redon S, Reichenbach P, Lingner J. The non-coding RNA TERRA is a natural ligand and direct inhibitor of human telomerase. Nucleic acids research, 2010, 38(17): 5797-5806.
22.Redon S, Zemp I, Lingner J. A three-state model for the regulation of telomerase by TERRA and hnRNPA1. Nucleic acids research, 2013, 41(19): 9117-9128.
23.Zhang JM, Yadav T, Ouyang J, Lan L, Zou L. Alternative Lengthening of Telomeres through Two Distinct Break-Induced Replication Pathways. Cell Rep. 2019;26(4):955-968
24.Dilley RL, Verma P, Cho NW, Winters HD, Wondisford AR, Greenberg RA. Break-induced telomere synthesis underlie alternative telomere maintenance. Nature. 2016;539(7627):54-58
25.Noordermeer SM, Adam S, Setiaputra D, Barazas M, Pettitt SJ, Ling AK, Olivieri M, Álvarez-Quilón A, Moatti N, Zimmermann M, Annunziato S, Krastev DB, Song F, Brandsma I, Frankum J, Brough R, Sherker A, Landry S, Szilard RK, Munro MM, McEwan A, Goullet de Rugy T, Lin ZY, Hart T, Moffat J, Gingras AC, Martin A, van Attikum H, Jonkers J, Lord CJ, Rottenberg S, Durocher D. The shieldin complex mediates 53BP1-dependent DNA repair.Nature. 2018;560(7716):117-121
26.Zlotorynski E. Telomerecrisis activates autophagic death. Nat Rev MolCell Biol. 2019;20(3):133
27.Cubiles MD, Barroso S, Vaquero-Sedas MI, Enguix A, Aguilera A, Vega-Palas MA. Epigenetic features of human telomeres. Nucleic Acids Res. 2018;46(5):2347-2355
28.Schmidt JC, Zaug AJ, Cech TR. Live Cell Imaging Reveals the Dynamics of Telomerase Recruitment to Telomeres. Cell 2016;166(5):1188-1197
29.Zhou Y, Cheunsuchon P, Nakayama Y, et al. Activation of paternally expressed genes and perinatal death caused by deletion of the Gtl2 gene. Development, 2010, 137(16): 2643-2652.
30.Stadtfeld M, Apostolou E, Akutsu H, Fukuda A, Follett P, Natesan S, Kono T, Shioda T, Hochedlinger K. Aberrant silencing of imprinted genes on chromosome 12qF1 in mouse induced pluripotent stem cells. Nature 2010;465(7295):175-81
31.Yu F, Geng W, Dong P, Huang Z, Zheng J.LncRNA-MEG3 inhibits activation of hepatic stellate cells through SMO protein and miR-212. Cell Death Dis. 2018;9(10):1014
32.Huang P, Huang FZ, Liu HZ, Zhang TY, Yang MS, Sun CZ. LncRNA MEG3 functions as a ceRNA in regulating hepatic lipogenesis by competitively binding to miR-21 with LRP6.Metabolism. 2019 Jan 31. pii: S0026-0495(19)30033-2.
33.Zhang X, Rice K, Wang Y, et al. Maternally expressed gene 3 (MEG3) noncoding ribonucleic acid: isoform structure, expression, and functions. Endocrinology, 2010, 151(3): 939-947.
34.Zhou Y, Zhang X, Klibanski A. MEG3 noncoding RNA: a tumor suppressor. Journal of molecular endocrinology, 2012, 48(3): R45-53.
Yan J, Guo X, Xia J, et al. MiR-148a regulates MEG3 in gastric cancer by targeting DNA methyltransferase 1. Medical oncology, 2014, 31(3): 879.
36.Liu LX, Deng W, Zhou XT, et al. The mechanism of adenosine-mediated activation of lncRNA MEG3 and its antitumor effects in human hepatoma cells. International journal of oncology, 2016, 48(1): 421-429.
37.Zhou Y, Zhong Y, Wang Y, et al. Activation of p53 by MEG3 non-coding RNA. The Journal of biological chemistry, 2007, 282(34): 24731-24742.
38.Wu M, Huang Y, Chen T, Wang W, Yang S, Ye Z, Xi X. LncRNA MEG3 inhibits the progression of prostate cancer by modulating miR-9-5p/QKI-5 axis.J Cell Mol Med. 2019;23(1):29-38
39.Zhang Y, Wu J, Jing H, Huang G, Sun Z, Xu S. Long noncoding RNA MEG3 inhibits breast cancer growth via upregulating endoplasmic reticulum stress and activating NF-κB and p53.J Cell Biochem. 2019;120(4):6789-6797
40.Jiang M, Wang YR, Xu N, Zhou L, An Q. Long noncoding RNA MEG3 play an important role in osteosarcoma development through sponging microRNAs.J Cell Biochem. 2019;120(4):5151-5159.
41.Lavin MF, Gueven N. The complexity of p53 stabilization and activation. Cell death and differentiation, 2006, 13(6): 941-950.
42.Harris SL, Levine AJ. The p53 pathway: positive and negative feedback loops. Oncogene, 2005, 24(17): 2899-2908.
43.Vousden KH, Prives C. Blinded by the Light: The Growing Complexity of p53. Cell, 2009, 137(3): 413-431.
44.Ghezraoui H, Oliveira C, Becker JR, Bilham K, Moralli D, Anzilotti C, Fischer R, Deobagkar-Lele M, Sanchiz-Calvo M, Fueyo-Marcos E, Bonham S, Kessler BM, Rottenberg S, Cornall RJ, Green CM, Chapman JR. 53BP1 cooperation with the REV7-shieldin complex underpins DNA structure-specific NHEJ.Nature. 2018;560(7716):122-127
45.Maya-Mendoza A, Moudry P, Merchut-Maya JM, Lee M, Strauss R, Bartek J. High speed of fork progression induces DNA replication stress and genomic instability. Nature. 2018;559(7713):279-284
46.Canzio D, Larson A, Narlikar GJ. Mechanisms of functional promiscuity by HP1 proteins. Trends in cell biology, 2014, 24(6): 377-386.
47 Maison C, Almouzni G. HP1 and the dynamics of heterochromatin maintenance. Nature reviews Molecular cell biology, 2004, 5(4): 296-304.
48.Eissenberg JC, Elgin SC. HP1a: a structural chromosomal protein regulating transcription. Trends in genetics : TIG, 2014, 30(3): 103-110.
49.Bosch-Presegue L, Raurell-Vila H, Thackray JK, et al. Mammalian HP1 Isoforms Have Specific Roles in Heterochromatin Structure and Organization. Cell reports, 2017, 21(8): 2048-2057.
50.Jensen KN, Lorincz MC. HP1 proteins safeguard embryonic stem cells.Nature. 2018;557(7707):640-641
51.Ostapcuk V, Mohn F, Carl SH, Basters A, Hess D, Iesmantavicius V, Lampersberger L, Flemr M, Pandey A, Thomä NH, Betschinger J, Bühler M. Activity-dependent neuroprotective protein recruits HP1 and CHD4 to control lineage-specifying genes. Nature. 2018;557(7707):739-743
52.Vizan P, Beringer M, Ballare C, et al. Role of PRC2-associated factors in stem cells and disease. The FEBS journal, 2015, 282(9): 1723-1735.
53.Margueron R, Reinberg D. The Polycomb complex PRC2 and its mark in life. Nature, 2011, 469(7330): 343-349.
54 Liu YL, Gao X, Jiang Y, et al. Expression and clinicopathological significance of EED, SUZ12 and EZH2 mRNA in colorectal cancer. Journal of cancer research and clinical oncology, 2015, 141(4): 661-669.
55.Manji SS, Sorensen BS, Klockars Tl. Molecular characterization and expression of maternally expressed gene 3 (Meg3/Gtl2) RNA in the mouse inner ear. Journal of neuroscience research, 2006, 83(2): 181-190.
56.Zhou Y, Cheunsuchon P, Nakayama Y. Activation of paternally expressed genes and perinatal death caused by deletion of the Gtl2 gene. Development, 2010, 137(16): 2643-2652.
57.He Y, Wu YT, Huang C. Inhibitory effects of long noncoding RNA MEG3 on hepatic stellate cells activation and liver fibrogenesis. Biochimica et biophysica acta, 2014, 1842(11): 2204-2215.
58.Chak WP, Lung RW, Tong JH. Downregulation of long non-coding RNA MEG3 in nasopharyngeal carcinoma. Molecular carcinogenesis, 2017, 56(3): 1041-1054.
59.Ying L, Huang Y, Chen H, et al. Downregulated MEG3 activates autophagy and increases cell proliferation in bladder cancer. Molecular bioSystems, 2013, 9(3): 407-411.
60.Sun M, Xia R, Jin F, et al. Downregulated long noncoding RNA MEG3 is associated with poor prognosis and promotes cell proliferation in gastric cancer. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine, 2014, 35(2): 1065-1073.
61.Lu KH LW, Liu XH, Sun M, et al. Long non-coding RNA MEG3 inhibits NSCLC cells proliferation and induces apoptosis by affecting p53 expression. BMC Cancer, 2013, 13: 461.
62.Li J, Bian EB, He XJ, et al. Epigenetic repression of long non-coding RNA MEG3 mediated by DNMT1 represses the p53 pathway in gliomas. International journal of oncology, 2016, 48(2): 723-733.
63.] Qin R, Chen Z, Ding Y, et al. Long non-coding RNA MEG3 inhibits the proliferation of cervical carcinoma cells through the induction of cell cycle arrest and apoptosis. Neoplasma, 2013, 60(5): 486-492.
64.Guo Q, Qian Z, Yan D, et al. LncRNA-MEG3 inhibits cell proliferation of endometrial carcinoma by repressing Notch signaling. Biomedicine & pharmacotherapy, 2016, 82: 589-594.
65.Xu XL, Xing BC, Han HB, et al. The properties of tumor-initiating cells from a hepatocellular carcinoma patient's primary and recurrent tumor. Carcinogenesis, 2010, 31(2): 167-174.
67.Li J, Chen JN, Zeng TT, et al. CD133+ liver cancer stem cells resist interferon-gamma-induced autophagy. BMC cancer, 2016, 16: 15.
67.Pflaum J, Schlosser S, Muller M. p53 Family and Cellular Stress Responses in Cancer. Frontiers in oncology, 2014, 4: 285.
68.Pflaum J, Schlosser S, Muller M. p53 Family and Cellular Stress Responses in Cancer. Frontiers in oncology, 2014, 4: 285.
69 Lavin MF, Gueven N. The complexity of p53 stabilization and activation. Cell death and differentiation, 2006, 13(6): 941-950.
70.Basu S, Murphy ME. Genetic Modifiers of the p53 Pathway. Cold Spring Harbor perspectives in medicine, 2016, 6(4): a026302.
71.Liou AT, Chen MF, Yang CW. Curcumin Induces p53-Null Hepatoma Cell Line Hep3B Apoptosis through the AKT-PTEN-FOXO4 Pathway. Evidence-based complementary and alternative medicine : eCAM, 2017, 2017: 4063865.
72.Soussi T, Lozano G. p53 mutation heterogeneity in cancer. Biochemical and biophysical research communications, 2005, 331(3): 834-842
73.Deshmukh A, Binju M, Arfuso F, et al. Role of epigenetic modulation in cancer stem cell fate. The international journal of biochemistry & cell biology, 2017, 90: 9-16.
74.Chan WM, Mak MC, Fung TK, et al. Ubiquitination of p53 at multiple sites in the DNA-binding domain. Molecular cancer research: MCR, 2006, 4(1): 15-25
75.Vizan P, Beringer M, Ballare C, et al. Role of PRC2-associated factors in stem cells and disease. The FEBS journal, 2015, 282(9): 1723-1735.
76.Margueron R, Reinberg D. The Polycomb complex PRC2 and its mark in life. Nature, 2011, 469(7330): 343-349.
77.Margueron R, Li G, Sarma K, et al. Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms. Molecular cell, 2008, 32(4): 503-518.
78.Conway E, Healy E, Bracken AP. PRC2 mediated H3K27 methylations in cellular identity and cancer. Current opinion in cell biology, 2015, 37: 42-48.
79.Chinaranagari S, Sharma P, Chaudhary J. EZH2 dependent H3K27me3 is involved in epigenetic silencing of ID4 in prostate cancer. Oncotarget, 2014, 5(16): 7172-7182.
80.Uysal F, Akkoyunlu G, Ozturk S. Dynamic expression of DNA methyltransferases (DNMTs) in oocytes and early embryos. Biochimie, 2015, 116: 103-113.
81.Esteller M. Epigenetics in cancer. The New England journal of medicine, 2008, 358(11): 1148-1159.
82.Eissenberg JC, Elgin SC. HP1a: a structural chromosomal protein regulating transcription. Trends in genetics: TIG, 2014, 30(3): 103-110.
83.Kirschmann DA, Lininger RA, Gardner LM, et al. Down-regulation of HP1Hsalpha expression is associated with the metastatic phenotype in breast cancer. Cancer research, 2000, 60(13): 3359-3363.
84.Cheng W, Tian L, Wang B, et al. Downregulation of HP1alpha suppresses proliferation of cholangiocarcinoma by restoring SFRP1 expression. Oncotarget, 2016, 7(30): 48107-48119.
85.Wang L, Xiao H, Zhang X, et al. The role of telomeres and telomerase in hematologic malignancies and hematopoietic stem cell transplantation. Journal of hematology & oncology, 2014, 7: 61.
86.Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature, 1990, 345(6274): 458-460.
87.Azzalin CM, Reichenbach P, Khoriauli L, et al. Telomeric repeat containing RNA and RNA surveillance factors at mammalian chromosome ends. Science, 2007, 318(5851): 798-801.
88.Blackburn EH EE, Lin J. Human telomere biology: A contributory and interactive factor in aging, disease risks, and protection. Science, 2015, 350(6265): 1193-1198.
89.Redon S, Reichenbach P, Lingner J. The non-coding RNA TERRA is a natural ligand and direct inhibitor of human telomerase. Nucleic acids research, 2010, 38(17): 5797-5806.
90.Greider CW, Blackburn EH. A telomeric sequence in the RNA of Tetrahymena telomerase required for telomere repeat synthesis. Nature, 1989, 337(6205): 331-337.
91.Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. European journal of cancer, 1997, 33(5): 787-791.
92.Yu X, Zheng H, Chan MT, et al. HULC: an oncogenic long non-coding RNA in human cancer. Journal of cellular and molecular medicine, 2017, 21(2): 410-417.
93.Wu M, Lin Z, Li X, et al. HULC cooperates with MALAT1 to aggravate liver cancer stem cells growth through telomere repeat-binding factor 2. Scientific reports, 2016, 6: 36045.